Janux Therapeutics (NASDAQ:JANX) Insider Sells $99,990.00 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 3,333 shares of the business’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $30.00, for a total transaction of $99,990.00. Following the completion of the sale, the insider owned 84,974 shares in the company, valued at $2,549,220. This represents a 3.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Andrew Hollman Meyer also recently made the following trade(s):

• On Tuesday, October 28th, Andrew Hollman Meyer sold 16,665 shares of Janux Therapeutics stock. The shares were sold at an average price of $30.06, for a total value of $500,949.90.

Janux Therapeutics Stock Up 6.6%

JANX traded up $1.82 during trading on Friday, reaching $29.28. The company had a trading volume of 1,318,767 shares, compared to its average volume of 1,121,612. The business has a 50 day simple moving average of $25.50 and a 200-day simple moving average of $25.19. Janux Therapeutics, Inc. has a 52 week low of $21.73 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.21. The business had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $3.07 million. On average, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Guggenheim assumed coverage on Janux Therapeutics in a report on Wednesday, September 3rd. They set a “buy” rating and a $72.00 target price for the company. Stifel Nicolaus reissued a “buy” rating and issued a $45.00 price target on shares of Janux Therapeutics in a research report on Wednesday, September 10th. Truist Financial assumed coverage on Janux Therapeutics in a research report on Wednesday, September 10th. They set a “buy” rating and a $100.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Janux Therapeutics in a report on Wednesday, October 8th. Finally, Barclays increased their price target on shares of Janux Therapeutics from $47.00 to $48.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $79.17.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quinn Opportunity Partners LLC lifted its holdings in Janux Therapeutics by 15.4% in the second quarter. Quinn Opportunity Partners LLC now owns 59,893 shares of the company’s stock valued at $1,384,000 after acquiring an additional 8,000 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Janux Therapeutics by 3.0% during the 1st quarter. New York State Common Retirement Fund now owns 16,435 shares of the company’s stock valued at $444,000 after purchasing an additional 471 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in shares of Janux Therapeutics by 88.0% in the 1st quarter. Cubist Systematic Strategies LLC now owns 75,860 shares of the company’s stock valued at $2,048,000 after purchasing an additional 35,511 shares during the period. Bank of New York Mellon Corp boosted its holdings in Janux Therapeutics by 13.3% during the first quarter. Bank of New York Mellon Corp now owns 89,370 shares of the company’s stock worth $2,413,000 after buying an additional 10,511 shares in the last quarter. Finally, AlphaQuest LLC boosted its holdings in Janux Therapeutics by 3,658.9% during the second quarter. AlphaQuest LLC now owns 9,698 shares of the company’s stock worth $224,000 after buying an additional 9,440 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.